January 18, 2017 / 12:40 AM / 8 months ago

BRIEF-Theratechnologies-Abstract submitted by Taimed for 24-week study of Ibalizumab phase III

Jan 17 (Reuters) - Theratechnologies Inc

* Theratechnologies-Abstract submitted by its partner, Taimed Biologics, for 24-week study of Ibalizumab phase III study has been selected for late breaker presentation Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below